Update on the clinical use of the low-molecular-weight heparin, parnaparin

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 819-831

  Camporese, Giuseppe ^a   Bernardi, Enrico ^b   Noventa, Franco ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Hospital of Conegliano Veneto   (Italy)

Author keywords

Acute coronary syndromes; Heparin; Low molecular weight heparin; Parnaparin; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; NADROPARIN; PARNAPARIN; PLACEBO; WARFARIN; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; VEIN OCCLUSION; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR DISEASE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VEIN THROMBOSIS;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 73949083877     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s3430     Document Type: Review

References (70)

1. Alexander JH, Singh KP. Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs. 2005;5(5):279-290.
2. Dettori AG. Parnaparin: a review of its pharmacological profile and clinical application. Drugs Today. 1995;31(1):19-35.
3. Frampton JE, Faulds D. Parnaparin: a review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs. 1994;47(4):652-676.
4. McKeage K, Keating GM. Parnaparin, A review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs. 2008;68(1):105-122.
5. Fluxum™. Summary of product characteristics. Bologna: Alfa Wassermann, 2007.
6. Maugeri N, de Gaetano G, Barbanti M, et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica. 2005;90(6):833-839.
7. Maugeri N, Di Fabio G, Barbanti M, et al. Parnaparin, a low- molecular-weight heparin, prevents P-select-independent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost. 2007;97(6):965-973.
8. Melandri G, Semprini F, Cervi V, et al. Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol. 1993;72(5):450-454.
9. Florian-Kujawski M, Hoppensteadt D, Maddineni J, et al. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins: pharmacologic implications. Int Angiol. 2004;23(4):346-354.
10. Verhaeghe R. The use of low-molecular-weight heparins in cardiovascular disease. Acta Cardiol. 1998;53(1):15-21.
11. Palareti G, Legnani C, Bianchini B, et al. Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecologic surgery patients. Int Angiol. 1989;8(1):47-52.
12. Dettori AG, Tagliaferri A, Dall'Aglio E, et al. Clinical pharmacology of a new low molecular weight heparin (alfa LMWH- Fluxum). Int Angiol. 1988;7(3 Suppl):7-18.
13. Di Stefano F, Giglio A, Vinci M, et al. Low molecular weight heparins for long-term therapy of peripheral vascular disease. Curr Ther Res. 1988;44(1):1-10.
14. Speziale F, Verardi S, Taurino M, et al. Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery. Pharmatherapeutica. 1988;5(4):261-268.
15. Garcea D, Martuzzi F, Santelmo N, et al. Post-surgical deep vein thrombosis prevention: evaluation of the risk/benefit ratio of fractionated and unfractionated heparin. Curr Med Res Opin. 1992;12(9):572-583.
16. Chiapuzzo E, Orengo GB, Ottria G, et al. The use of low molecular weight heparins for post-surgical deep vein thrombosis prevention in orthopaedic patients. J Int Med Res. 1988;16(5):359-366.
17. Legnani C, Imberti D, Cini M, et al. Pharmacodynamic of low molecular weight heparin (LMWH) in obese subjects undergoing bariatric surgery: a prospective randomised study comparing two different doses of parnaparin [abstract no. P153] Haematologica. 2006; 91 Suppl 2:89. Plus poster presented a the XIX Congress of the Italian Society for Studies on Hemostasis and Thrombosis; 2006 Sep 14-17: Milan.
18. Melandri G, Branzi A, Semprini F, et al. Effects of two dosages of subcutaneous low molecular weight heparin (parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction. Thromb Res. 1992;66(2-3):141-150.
19. Mannarino E, Pasqualini L, Innocente S, et al. Eff icacy of low- molecular-weight heparin in the management of intermittent claudication. Angiology. 1991;42(1):1-7.
20. Calabrò A, Piarulli F, Milan D, et al. Clinical assessment of low molecular weight heparin effects in peripheral vascular disease. Angiology. 1993;44(3):188-195.
21. PRIME CARE Study Investigators Group. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study. Indian Heart J. 2005;57(6):648-654.
22. Forestieri P, Quarto G, De Caterina M, et al. Prophylaxis of thromboembolism in bariatric surgery with parnaparin. Obes Surg. 2007;17(12):1558-1562.
23. Wang XK, Zhang Y, Yang CM, et al. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction. Clin Drug Invest. 2006;26(6):341-349.
24. Wong GC, Giugliano RP. Low-molecular-weight heparins for the treatment of acute coronary syndromes. Semin Vasc Med. 2003;3(4):391-402.
25. Dettori AG, Babbini M. Human pharmacology of a low-molecular-weight heparin (alfa-LMWH): an update. Med Res Rev. 1992;12(4):373-389.
26. Agrati AM, Ambrosi G, Spinelli G, et al. Influence of the administration site on the bioavailability of a new low molecular weight heparin administered by subcutaneous route. Aggiornamenti di Medicina e Chirurgia. 1991;9(3):375-379.
27. Palmieri GC, Ambrosi G, Ferrero G. Kinetic control in healthy volunteers of low molecular weight heparin antithrombotic activity. Riv Eur Sci Med Farmacol. 1988;10:187-192.
28. Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent postoperative deep venous thrombosis. Curr Med Res Opin. 1988;11(2):80-86.
29. Forzano F, Nicora E. Assessment of efficacy and tolerance of a new low molecular weight heparin in post-operative thromboembolic prophylaxis. Aggior Med Chir. 1989;7:1-9.
30. Pini M, Tagliaferri A, Manotti C, et al. Low molecular weight heparin (alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Int Angiol. 1989;8(3):134-139.
31. Beghi C, Fragnito C, Antonelli A, et al. Prevention of deep venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery. Int Angiol. 1993;12(4):383-386.
32. Verardi S, Casciani CU, Nicora E, et al. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Int Angiol. 1988;7(3 Suppl):19-24.
33. Mascali F, Condorelli A, Salanitiri G, et al. Postsurgery thromboembolism prevention by LMW heparin subcutaneous administration. Eur Rev Med Pharmacol Sci. 1988;10:135-141.
34. Verardi F, Cortese F, Baroni B. Deep vein thrombosis prevention in surgical patients: effectiveness and safety of a new a low molecular weight heparin. Curr Ther Res. 1989;46:366-372.
35. Catania G, Salanitri G. Prevention of postoperative deep vein thrombosis by two different heparin types. Int J Clin Pharmacol. 1988;26:304-309.
36. Gruttadauria G, Ferrara C, Musumeci S. Subcutaneous low-molecular weight heparin for postsurgical thromboembolism prevention. Med Praxis. 1988;9(4):1-9.
37. Salcuni PF, Azzarone M, Palazzini E. A new low molecular weight heparin for deep vein thrombosis prevention: effectiveness in postoperative patients. Curr Ther Res. 1988;43:824-831.
38. Corrado F, Fini M, Severini G, et al. Low-molecular weight heparin (Fluxum) prevention of post-operative thrombosis in urological surgery. A controlled study. Clin Trials J. 1988;26:138-148.
39. Bonomo GM, Scattarella M, Treglia AL. Preventing postsurgery thromboembolism by a new low molecular weight heparin. Med Praxis. 1988;9(4):1-7.
40. Gossetti B, Irace L, Gattuso R, et al. Prevention of deep venous thrombosis in vascular surgical procedures by LMW-heparin. Inter Angio. 1988;7 Suppl 3:25-27.
41. Gossetti B, Irace L, Venosi S, et al. Low-molecular weight heparin in prevention of deep vein thrombosis prevention in major vascular surgery. Phlébologie. 1992;92:456-458.
42. Pellegrino A, BAlta D, De Girolamo C, et al. Prevention of post-surgical deep vein thrombosis in urology. Prophylactic use of a new low molecular weight heparin. Clinical Trials Journal. 1988;25:164-171.
43. Cortellini P, Pelletti F, Simonazzi M.P, et al. Prevention of post-operative thromboembolism. A clinical trial in urological patients treated with a new low molecular weight heparin. Acta Ther. 1988;14:135-144.
44. Tartaglia P, Perolo F, D'Ales A. Effectiveness of prevention with a low molecular weight heparin preparation in gynecological patients undergoing surgery: an open study. Curr Med Res Opin. 1989;11(6):360-365.
45. Montebugnoli M, Bugamelli S, Calo P, et al. Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin. Clin Appl Thromb Hemost. 2007;13(3):249-258.
46. Notarbartolo A, Salanitri G, Davì G, Averna M, Barbagallo C, Catalano I. Low-molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Med Praxis. 1988;9(4):1-13.
47. Teoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clinical Trials Metaanal. 1993;28:215-225.
48. Vashist MG, Kapoor S, Dhingra A, et al. Is low molecular weight heparin effective and safe in the management of deep vein thrombosis? A prospective randomized study. Ind Med Gaz. 2006;140:175-178.
49. Bellosta R, Ferrari P, Luzzani L, et al. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations. Angiology. 2007;58(3):316-322.
50. Zinicola N, Cerruti R. Deep vein thrombosis of the lower limbs: results of long term treatment with a new low-molecular weight heparin. Farmaci e terapia. 1989;3:147-151.
51. Verardi S, Ippoliti A, Pistolese GR. Antithrombotic treatment during acute inflammatory complications of patients affected by postphlebytic syndrome: LMW-heparin versus standard heparin. Int Angiol. 1988;7 Suppl 3:33-40.
52. Sannazzari P. Low molecular weight heparin in the symptomatic treatment of chronic venous insufficiency: controlled double blind study vs calcium heparin. Panminerva Med. 1989;31(3):127-133.
53. Catania G, Salanitri T. Heparin therapy of post-phlebitic syndrome: results of a single-blind, clinical trial of parnaparin vs calcium heparin. Stampa Medica Europea. 1993;13:17-27.
54. Canova R, Celentano R, Gasbarrone L. Long-term treatment of patients with post-phlebitic syndrome by means of a new lmw heparin. NAM. 1993;9:318-324.
55. Della Marchina M, Renzi G, Renzi C, et al. Low molecular weight heparins in chronic venous insufficiency: controlled trial of parnaparin efficacy and tolerability. Br J Clin Res. 1993;4:29-36.
56. Mannarino E, Pasqualini L, Innocente S, et al. Efficacy of low- molecular-weight heparin in the management of intermittent claudication. Angiology. 1991;42(1):1-7.
57. Calabrò A, Piarulli F, Milan D, et al. Clinical assessment of low molecular weight heparin effects in peripheral vascular disease. Angiology. 1993;44(3):188-195.
58. Simoni G, Lucertini G, Decian F. Low molecular weight heparins: therapeutic insight in peripheral arterial occlusive disease. Clin Trials Metaanal. 1993;28:137-145.
59. Tesi M, Bronchi GM, C Arini A, et al. Efficacy and safety of a new low-molecular weight heparin in the medium-term treatment of atherosclerotic arteriopathy of the lower limbs. J Drug Dev. 1989;2:73-82.
60. Serrao E, Mangialardi N. Treatment of peripheral arteriopathies with a new low weight heparin. Panminerva Medica. 1991;33:197-204.
61. Palmieri G, Ambrosi G, Agrati AM, et al. A new low molecular weight heparin in the treatment of peripheral arterial disease. Int Angiol. 1988;7 Suppl 3:41-47.
62. Melandri G, Semprini F, Cervi V, et al. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: a double-blind, randomized, placebo- controlled trial. Circulation. 1993;88:2517-2523.
63. Pastorelli L, Saibeni S, Spina L, et al. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2008;28(5):581-588.
64. Imberti D, Baldini E, Nicolini A, et al. Farmacodinamica dell'eparina a basso peso molecolare in pazienti sottoposti a intervento di chirurgia bariatrica: studio prospettico randomizzato tra due differenti dosi di parnaparin (studio BAFLUX). Atti XVI Congresso Nazionale SICOB; 2008.
65. Ageno W, Cattaneo R, Manfredi E, et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Atti XX Congresso Nazionale della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET), Firenze, 2008. Haematologica. 2008;93 Suppl 3:33:CO98.
66. Luttichau U, Palazzini E. Antithrombotic therapy in phlebopathies of lower limbs: a controlled study of low molecular weight heparin versus heparin calcium. Eur Rev Med Pharmacol Sci. 1989;11:351-358.
67. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular- weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
68. Prandoni P, Siragusa S, Girolami B, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049-3054.
69. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Eightieth ACCP Conference on Anti- thrombotic and Thrombolytic Therapy. Chest. 2008;133(6 Suppl):381S-453S.
70. Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. The British Committee for Standards in Haematology. Br J Haematol. 2006;133(1):19-34.